Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas

NCT02611700 is registered in ClinicalTrials.gov with Biotech Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02611700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02611700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas
Lead sponsor
Biotech Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2015
Completion date
June 30, 2019
Enrollment
504 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinomas